|
Daily Medical Update
Irritable Bowel Syndrome (IBS-C vs IBS-D treatments)
Thursday, February 19, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Journal of Gastrointestinal and Liver Diseases (2025) - Network Meta-Analysis
Key Findings
- Across 16 trials, linaclotide 290 µg daily and tenapanor 50 mg BID improved IBS-C abdominal pain and bowel outcomes versus placebo.
- Higher-dose regimens improved efficacy but increased adverse events, including more side effects with linaclotide 125 µg and tenapanor 50 mg BID versus lower-dose comparators.
📋 Practice Implication: For IBS-C, escalate to evidence-supported secretagogues/prokinetics using dose-specific risk-benefit counseling rather than class-level prescribing.
|
Journal of Medical Internet Research (2026) - Network Meta-Analysis
Key Findings
- Across 22 studies (n=3,161), face-to-face CBT showed similar effects to digital, self-help, and telephone CBT for IBS symptom outcomes.
- Evidence certainty was low with insufficient effective sample sizes for several modality comparisons, but remote formats remained clinically promising.
📋 Practice Implication: Primary care can offer digitally delivered CBT as a legitimate access-expanding option when GI psychology access is limited.
|
Clinical Biochemistry (2026) - Systematic Review/Meta-Analysis
Key Findings
- Among 24 studies (n=9,343), urinary metabolite panels showed high pooled sensitivity (0.988) and specificity (0.934).
- Fecal peptidase activity showed sensitivity 0.905 and specificity 0.883, while RAID-IBS showed sensitivity 0.935 and specificity 0.919 in pooled analyses.
📋 Practice Implication: Emerging biomarker panels may become useful rule-in/rule-out tools to shorten time to confident IBS diagnosis in primary care.
|
BMC Gastroenterology (2025) - Randomized Trial Subanalysis
Key Findings
- In a 445-patient primary care cohort, baseline inflammatory markers did not correlate with IBS symptom severity or predict treatment response.
- FODMAP-based intervention improved symptoms over standard medication in the parent trial, while biomarker shifts were not clinically predictive.
📋 Practice Implication: Do not order routine inflammatory biomarker panels to phenotype typical IBS; prioritize symptom-based management and dietary intervention.
|
|
Recent IBS evidence supports more subtype-specific management in primary care: dose-aware pharmacologic choices for IBS-C and broader use of accessible behavioral therapy formats. Diagnostic strategy is also shifting, with promising biomarker panels on the horizon while routine inflammatory markers remain low-yield for typical IBS triage. Together, these findings favor precision treatment plus smarter testing rather than reflexive broad lab work.
|
|